Targeting cellular metabolism to improve cancer therapeutics (original) (raw)

• Vander Heiden MG, Cantley LC, Thompson CB . Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science 2009; 324: 1029–1033.
  Article CAS PubMed PubMed Central Google Scholar
• Warburg O . On respiratory impairment in cancer cells. Science 1956; 124: 269–270.
  CAS PubMed Google Scholar
• Kim JW, Dang CV . Cancer's molecular sweet tooth and the Warburg effect. Cancer Res 2006; 66: 8927–8930.
  Article CAS PubMed Google Scholar
• Chen Z, Lu W, Garcia-Prieto C, Huang P . The Warburg effect and its cancer therapeutic implications. J Bioenerget Biomembranes 2007; 39: 267–274.
  Article CAS Google Scholar
• Gatenby RA, Gillies RJ . Glycolysis in cancer: a potential target for therapy. Int J Biochem Cell Biol 2007; 39: 1358–1366.
  Article CAS PubMed Google Scholar
• Kroemer G, Pouyssegur J . Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 2008; 13: 472–482.
  Article CAS PubMed Google Scholar
• DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB . The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metabol 2008; 7: 11–20.
  Article CAS Google Scholar
• Gillies RJ, Robey I, Gatenby RA . Causes and consequences of increased glucose metabolism of cancers. J Nucl Med 2008; 49 (Suppl 2): 24S–42S.
  Article CAS PubMed Google Scholar
• Hsu PP, Sabatini DM . Cancer cell metabolism: Warburg and beyond. Cell 2008; 134: 703–707.
  Article CAS PubMed Google Scholar
• Pandey PR, Liu W, Xing F, Fukuda K, Watabe K . Anti-cancer drugs targeting fatty acid synthase (FAS). Recent Patents Anti-Cancer Drug Discovery 2012; 7: 185–197.
  Article CAS PubMed Google Scholar
• Erickson JW, Cerione RA . Glutaminase: a hot spot for regulation of cancer cell metabolism? Oncotarget 2010; 1: 734–740.
  PubMed PubMed Central Google Scholar
• Wise DR, Thompson CB . Glutamine addiction: a new therapeutic target in cancer. Trends Biochem Sci 2010; 35: 427–433.
  Article CAS PubMed PubMed Central Google Scholar
• Dang CV . Links between metabolism and cancer. Genes Dev 2012; 26: 877–890.
  Article CAS PubMed PubMed Central Google Scholar
• Munoz-Pinedo C, El Mjiyad N, Ricci JE . Cancer metabolism: current perspectives and future directions. Cell Death Disease 2012; 3: e248.
  Article CAS PubMed PubMed Central Google Scholar
• Birsoy K, Sabatini DM, Possemato R . Untuning the tumor metabolic machine: targeting cancer metabolism: a bedside lesson. Nat Med 2012; 18: 1022–1023.
  Article CAS PubMed Google Scholar
• Dang CV, Hamaker M, Sun P, Le A, Gao P . Therapeutic targeting of cancer cell metabolism. J Mol Med (Berlin, Germany) 2011; 89: 205–212.
  Article CAS Google Scholar
• El Mjiyad N, Caro-Maldonado A, Ramirez-Peinado S, Munoz-Pinedo C . Sugar-free approaches to cancer cell killing. Oncogene 2010; 30: 253–264.
  Article PubMed CAS Google Scholar
• Hamanaka RB, Chandel NS . Targeting glucose metabolism for cancer therapy. J Exp Med 2012; 209: 211–215.
  Article CAS PubMed PubMed Central Google Scholar
• Jones NP, Schulze A . Targeting cancer metabolism--aiming at a tumour’s sweet-spot. Drug Discovery Today 2012; 17: 232–241.
  Article CAS PubMed Google Scholar
• Tennant DA, Duran RV, Gottlieb E . Targeting metabolic transformation for cancer therapy. Nat Rev 2010; 10: 267–277.
  Article CAS Google Scholar
• Vander Heiden MG . Targeting cancer metabolism: a therapeutic window opens. Nat Rev Drug Discov 2011; 10: 671–684.
  Article CAS PubMed Google Scholar
• Liu H, Liu Y, Zhang JT . A new mechanism of drug resistance in breast cancer cells: fatty acid synthase overexpression-mediated palmitate overproduction. Mol Cancer Therapeutics 2008; 7: 263–270.
  Article CAS Google Scholar
• Zhao Y, Liu H, Liu Z, Ding Y, Ledoux SP, Wilson GL et al. Overcoming trastuzumab resistance in breast cancer by targeting dysregulated glucose metabolism. Cancer Res 2011; 71: 4585–4597.
  Article CAS PubMed PubMed Central Google Scholar
• Zhou M, Zhao Y, Ding Y, Liu H, Liu Z, Fodstad O et al. Warburg effect in chemosensitivity: targeting lactate dehydrogenase-A re-sensitizes taxol-resistant cancer cells to taxol. Mol Cancer 2010; 9: 33.
  Article PubMed PubMed Central Google Scholar
• Wang JB, Erickson JW, Fuji R, Ramachandran S, Gao P, Dinavahi R et al. Targeting mitochondrial glutaminase activity inhibits oncogenic transformation. Cancer Cell 2010; 18: 207–219.
  Article CAS PubMed PubMed Central Google Scholar
• Macheda ML, Rogers S, Best JD . Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol 2005; 202: 654–662.
  Article CAS PubMed Google Scholar
• Cao X, Fang L, Gibbs S, Huang Y, Dai Z, Wen P et al. Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia. Cancer Chemotherapy Pharmacol 2007; 59: 495–505.
  Article CAS Google Scholar
• McBrayer SK, Cheng JC, Singhal S, Krett NL, Rosen ST, Shanmugam M . Multiple myeloma exhibits novel dependence on GLUT4, GLUT8, and GLUT11: implications for glucose transporter-directed therapy. Blood 2012; 119: 4686–4697.
  Article CAS PubMed PubMed Central Google Scholar
• Liu Y, Cao Y, Zhang W, Bergmeier S, Qian Y, Akbar H et al. A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo. Mol Cancer Therapeutics 2012; 11: 1672–1682.
  Article CAS Google Scholar
• Monti E, Gariboldi MB . HIF-1 as a target for cancer chemotherapy, chemosensitization and chemoprevention. Curr Mol Pharmacol 2011; 4: 62–77.
  Article CAS PubMed Google Scholar
• Le Calve B, Rynkowski M, Le Mercier M, Bruyere C, Lonez C, Gras T et al. Long-term in vitro treatment of human glioblastoma cells with temozolomide increases resistance in vivo through up-regulation of GLUT transporter and aldo-keto reductase enzyme AKR1C expression. Neoplasia (New York), NY 2010; 12: 727–739.
  Article CAS Google Scholar
• Maher JC, Krishan A, Lampidis TJ . Greater cell cycle inhibition and cytotoxicity induced by 2-deoxy-D-glucose in tumor cells treated under hypoxic vs aerobic conditions. Cancer Chemother Pharmacol 2004; 53: 116–122.
  Article CAS PubMed Google Scholar
• Pelicano H, Martin DS, Xu RH, Huang P . Glycolysis inhibition for anticancer treatment. Oncogene 2006; 25: 4633–4646.
  Article CAS PubMed Google Scholar
• Kurtoglu M, Gao N, Shang J, Maher JC, Lehrman MA, Wangpaichitr M et al. Under normoxia, 2-deoxy-D-glucose elicits cell death in select tumor types not by inhibition of glycolysis but by interfering with N-linked glycosylation. Mol Cancer Therapeutics 2007; 6: 3049–3058.
  Article CAS Google Scholar
• Maschek G, Savaraj N, Priebe W, Braunschweiger P, Hamilton K, Tidmarsh GF et al. 2-deoxy-D-glucose increases the efficacy of adriamycin and paclitaxel in human osteosarcoma and non-small cell lung cancers in vivo. Cancer Res 2004; 64: 31–34.
  Article CAS PubMed Google Scholar
• Dwarakanath B, Jain V . Targeting glucose metabolism with 2-deoxy-D-glucose for improving cancer therapy. Fut Oncol (London, England) 2009; 5: 581–585.
  Article CAS Google Scholar
• Youle RJ, Strasser A . The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol 2008; 9: 47–59.
  Article CAS PubMed Google Scholar
• Coloff JL, Macintyre AN, Nichols AG, Liu T, Gallo CA, Plas DR et al. Akt-dependent glucose metabolism promotes Mcl-1 synthesis to maintain cell survival and resistance to Bcl-2 inhibition. Cancer Res 2011; 71: 5204–5213.
  Article CAS PubMed PubMed Central Google Scholar
• Meynet O, Beneteau M, Jacquin MA, Pradelli LA, Cornille A, Carles M et al. Glycolysis inhibition targets Mcl-1 to restore sensitivity of lymphoma cells to ABT-737-induced apoptosis. Leukemia 2012; 26: 1145–1147.
  Article CAS PubMed Google Scholar
• Yamaguchi R, Janssen E, Perkins G, Ellisman M, Kitada S, Reed JC . Efficient elimination of cancer cells by deoxyglucose-ABT-263/737 combination therapy. PloS one 2011; 6: e24102.
  Article CAS PubMed PubMed Central Google Scholar
• Pradelli LA, Beneteau M, Chauvin C, Jacquin MA, Marchetti S, Munoz-Pinedo C et al. Glycolysis inhibition sensitizes tumor cells to death receptors-induced apoptosis by AMP kinase activation leading to Mcl-1 block in translation. Oncogene 2010; 29: 1641–1652.
  Article CAS PubMed Google Scholar
• Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L et al. Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20: 1800–1808.
  Article CAS PubMed Google Scholar
• Lan KH, Lu CH, Yu D . Mechanisms of trastuzumab resistance and their clinical implications. Ann N Y Acad Sci 2005; 1059: 70–75.
  Article CAS PubMed Google Scholar
• Hudis CA . Trastuzumab--mechanism of action and use in clinical practice. N Engl J Med 2007; 357: 39–51.
  Article CAS PubMed Google Scholar
• Zhang H, Berezov A, Wang Q, Zhang G, Drebin J, Murali R et al. ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest 2007; 117: 2051–2058.
  Article CAS PubMed PubMed Central Google Scholar
• Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783–792.
  Article CAS PubMed Google Scholar
• Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004; 6: 117–127.
  Article CAS PubMed Google Scholar
• Nahta R, Yu D, Hung MC, Hortobagyi GN, Esteva FJ . Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Practice 2006; 3: 269–280.
  CAS Google Scholar
• Zhao YH, Zhou M, Liu H, Ding Y, Khong HT, Yu D et al. Upregulation of lactate dehydrogenase A by ErbB2 through heat shock factor 1 promotes breast cancer cell glycolysis and growth. Oncogene 2009; 28: 3689–3701.
  Article CAS PubMed Google Scholar
• Geschwind JF, Georgiades CS, Ko YH, Pedersen PL . Recently elucidated energy catabolism pathways provide opportunities for novel treatments in hepatocellular carcinoma. Expert Rev Anticancer Therapy 2004; 4: 449–457.
  Article CAS Google Scholar
• Ko YH, Pedersen PL, Geschwind JF . Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase. Cancer Lett 2001; 173: 83–91.
  Article CAS PubMed Google Scholar
• Nakano A, Tsuji D, Miki H, Cui Q, El Sayed SM, Ikegame A et al. Glycolysis inhibition inactivates ABC transporters to restore drug sensitivity in malignant cells. PloS One 2011; 6: e27222.
  Article CAS PubMed PubMed Central Google Scholar
• Zhou Y, Tozzi F, Chen J, Fan F, Xia L, Wang J et al. Intracellular ATP levels are a pivotal determinant of chemoresistance in colon cancer cells. Cancer Res 2012; 72: 304–314.
  Article CAS PubMed Google Scholar
• Hulleman E, Kazemier KM, Holleman A, VanderWeele DJ, Rudin CM, Broekhuis MJ et al. Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells. Blood 2009; 113: 2014–2021.
  Article CAS PubMed PubMed Central Google Scholar
• Zhao Y, Liu H, Riker AI, Fodstad O, Ledoux SP, Wilson GL et al. Emerging metabolic targets in cancer therapy. Front Biosci 2011; 16: 1844–1860.
  Article CAS PubMed Central Google Scholar
• Hitosugi T, Kang S, Vander Heiden MG, Chung TW, Elf S, Lythgoe K et al. Tyrosine phosphorylation inhibits PKM2 to promote the Warburg effect and tumor growth. Sci Signal 2009; 2: ra73.
  Article PubMed PubMed Central CAS Google Scholar
• Christofk HR, Vander Heiden MG, Harris MH, Ramanathan A, Gerszten RE, Wei R et al. The M2 splice isoform of pyruvate kinase is important for cancer metabolism and tumour growth. Nature 2008; 452: 230–233.
  Article CAS PubMed Google Scholar
• Li SL, Ye F, Cai WJ, Hu HD, Hu P, Ren H et al. Quantitative proteome analysis of multidrug resistance in human ovarian cancer cell line. J Cell Biochem 2010; 109: 625–633.
  CAS PubMed Google Scholar
• Martinez-Balibrea E, Plasencia C, Gines A, Martinez-Cardus A, Musulen E, Aguilera R et al. A proteomic approach links decreased pyruvate kinase M2 expression to oxaliplatin resistance in patients with colorectal cancer and in human cell lines. Molr Cancer Therapeutics 2009; 8: 771–778.
  Article CAS Google Scholar
• Yoo BC, Ku JL, Hong SH, Shin YK, Park SY, Kim HK et al. Decreased pyruvate kinase M2 activity linked to cisplatin resistance in human gastric carcinoma cell lines. Int J Cancer 2004; 108: 532–539.
  Article CAS PubMed Google Scholar
• Shin YK, Yoo BC, Hong YS, Chang HJ, Jung KH, Jeong SY et al. Upregulation of glycolytic enzymes in proteins secreted from human colon cancer cells with 5-fluorouracil resistance. Electrophoresis 2009; 30: 2182–2192.
  Article CAS PubMed Google Scholar
• Guo W, Zhang Y, Chen T, Wang Y, Xue J, Zhang Y et al. Efficacy of RNAi targeting of pyruvate kinase M2 combined with cisplatin in a lung cancer model. J Cancer Res Clin Oncol 2011; 137: 65–72.
  Article CAS PubMed Google Scholar
• Shi HS, Li D, Zhang J, Wang YS, Yang L, Zhang HL et al. Silencing of pkm2 increases the efficacy of docetaxel in human lung cancer xenografts in mice. Cancer Sci 2010; 101: 1447–1453.
  Article CAS PubMed Google Scholar
• Fantin VR, St-Pierre J, Leder P . Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 2006; 9: 425–434.
  Article CAS PubMed Google Scholar
• Xie H, Valera VA, Merino MJ, Amato AM, Signoretti S, Linehan WM et al. LDH-A inhibition, a therapeutic strategy for treatment of hereditary leiomyomatosis and renal cell cancer. Mol Cancer Therapeutics 2009; 8: 626–635.
  Article CAS Google Scholar
• Le A, Cooper CR, Gouw AM, Dinavahi R, Maitra A, Deck LM et al. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci USA 2010; 107: 2037–2042.
  Article CAS PubMed PubMed Central Google Scholar
• Khaleque MA, Bharti A, Gong J, Gray PJ, Sachdev V, Ciocca DR et al. Heat shock factor 1 represses estrogen-dependent transcription through association with MTA1. Oncogene 2008; 27: 1886–1893.
  Article CAS PubMed Google Scholar
• Khaleque MA, Bharti A, Sawyer D, Gong J, Benjamin IJ, Stevenson MA et al. Induction of heat shock proteins by heregulin beta1 leads to protection from apoptosis and anchorage-independent growth. Oncogene 2005; 24: 6564–6573.
  Article CAS PubMed Google Scholar
• Min JN, Huang L, Zimonjic DB, Moskophidis D, Mivechi NF . Selective suppression of lymphomas by functional loss of Hsf1 in a p53-deficient mouse model for spontaneous tumors. Oncogene 2007; 26: 5086–5097.
  Article CAS PubMed Google Scholar
• Dai C, Whitesell L, Rogers AB, Lindquist S . Heat shock factor 1 is a powerful multifaceted modifier of carcinogenesis. Cell 2007; 130: 1005–1018.
  Article CAS PubMed PubMed Central Google Scholar
• Lu CW, Lin SC, Chen KF, Lai YY, Tsai SJ . Induction of pyruvate dehydrogenase kinase-3 by hypoxia-inducible factor-1 promotes metabolic switch and drug resistance. J Biol Chem 2008; 283: 28106–28114.
  Article CAS PubMed PubMed Central Google Scholar
• Lu CW, Lin SC, Chien CW, Lin SC, Lee CT, Lin BW et al. Overexpression of pyruvate dehydrogenase kinase 3 increases drug resistance and early recurrence in colon cancer. Am J Pathol 2011; 179: 1405–1414.
  Article CAS PubMed PubMed Central Google Scholar
• Kato M, Li J, Chuang JL, Chuang DT . Distinct structural mechanisms for inhibition of pyruvate dehydrogenase kinase isoforms by AZD7545, dichloroacetate, and radicicol. Structure 2007; 15: 992–1004.
  Article CAS PubMed PubMed Central Google Scholar
• Bonnet S, Archer SL, Allalunis-Turner J, Haromy A, Beaulieu C, Thompson R et al. A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 2007; 11: 37–51.
  Article CAS PubMed Google Scholar
• Cao W, Yacoub S, Shiverick KT, Namiki K, Sakai Y, Porvasnik S et al. Dichloroacetate (DCA) sensitizes both wild-type and over expressing Bcl-2 prostate cancer cells in vitro to radiation. Prostate 2008; 68: 1223–1231.
  Article CAS PubMed Google Scholar
• Michelakis ED, Webster L, Mackey JR . Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer. Br J Cancer 2008; 99: 989–994.
  Article CAS PubMed PubMed Central Google Scholar
• Sun RC, Fadia M, Dahlstrom JE, Parish CR, Board PG, Blackburn AC . Reversal of the glycolytic phenotype by dichloroacetate inhibits metastatic breast cancer cell growth in vitro and in vivo. Breast Cancer Res Treat 2010; 120: 253–260.
  Article CAS PubMed Google Scholar
• Wong JY, Huggins GS, Debidda M, Munshi NC, De Vivo I . Dichloroacetate induces apoptosis in endometrial cancer cells. Gynecologic Oncol 2008; 109: 394–402.
  Article CAS Google Scholar
• Ishiguro T, Ishiguro M, Ishiguro R, Iwai S . Cotreatment with dichloroacetate and omeprazole exhibits a synergistic antiproliferative effect on malignant tumors. Oncol Lett 2012; 3: 726–728.
  Article CAS PubMed PubMed Central Google Scholar
• Ishiguro T, Ishiguro R, Ishiguro M, Iwai S . Co-treatment of dichloroacetate, omeprazole and tamoxifen exhibited synergistically antiproliferative effect on malignant tumors: in vivo experiments and a case report. Hepato-gastroenterology 2012; 59: 994–996.
  CAS PubMed Google Scholar
• Tong J, Xie G, He J, Li J, Pan F, Liang H . Synergistic antitumor effect of dichloroacetate in combination with 5-fluorouracil in colorectal cancer. J Biomed Biotechnol 2011; 2011: 740564.
  Article PubMed PubMed Central CAS Google Scholar
• Ayyanathan K, Kesaraju S, Dawson-Scully K, Weissbach H . Combination of sulindac and dichloroacetate kills cancer cells via oxidative damage. PloS One 2012; 7: e39949.
  Article CAS PubMed PubMed Central Google Scholar
• Flavin R, Peluso S, Nguyen PL, Loda M . Fatty acid synthase as a potential therapeutic target in cancer. Fut Oncol (London, England) 2010; 6: 551–562.
  Article CAS Google Scholar
• Menendez JA, Lupu R, Colomer R . Inhibition of tumor-associated fatty acid synthase hyperactivity induces synergistic chemosensitization of HER -2/ neu -overexpressing human breast cancer cells to docetaxel (taxotere). Breast Cancer Res Treatment 2004; 84: 183–195.
  Article CAS Google Scholar
• Vazquez-Martin A, Colomer R, Brunet J, Menendez JA . Pharmacological blockade of fatty acid synthase (FASN) reverses acquired autoresistance to trastuzumab (Herceptin by transcriptionally inhibiting 'HER2 super-expression' occurring in high-dose trastuzumab-conditioned SKBR3/Tzb100 breast cancer cells. Int J Oncol 2007; 31: 769–776.
  CAS PubMed Google Scholar
• Yang Y, Liu H, Li Z, Zhao Z, Yip-Schneider M, Fan Q et al. Role of fatty acid synthase in gemcitabine and radiation resistance of pancreatic cancers. Int J Biochem Mol Biol 2011; 2: 89–98.
  CAS PubMed PubMed Central Google Scholar
• Thupari JN, Pinn ML, Kuhajda FP . Fatty acid synthase inhibition in human breast cancer cells leads to malonyl-CoA-induced inhibition of fatty acid oxidation and cytotoxicity. Biochem Biophys Res Commun 2001; 285: 217–223.
  Article CAS PubMed Google Scholar
• Li JN, Gorospe M, Chrest FJ, Kumaravel TS, Evans MK, Han WF et al. Pharmacological inhibition of fatty acid synthase activity produces both cytostatic and cytotoxic effects modulated by p53. Cancer Res 2001; 61: 1493–1499.
  CAS PubMed Google Scholar
• Little JL, Wheeler FB, Fels DR, Koumenis C, Kridel SJ . Inhibition of fatty acid synthase induces endoplasmic reticulum stress in tumor cells. Cancer Res 2007; 67: 1262–1269.
  Article CAS PubMed Google Scholar
• Pizer ES, Chrest FJ, DiGiuseppe JA, Han WF . Pharmacological inhibitors of mammalian fatty acid synthase suppress DNA replication and induce apoptosis in tumor cell lines. Cancer Res 1998; 58: 4611–4615.
  CAS PubMed Google Scholar
• Menendez JA, Vellon L, Mehmi I, Oza BP, Ropero S, Colomer R et al. Inhibition of fatty acid synthase (FAS) suppresses HER2/neu (erbB-2) oncogene overexpression in cancer cells. Proc Natl Acad Sci USA 2004; 101: 10715–10720.
  Article CAS PubMed PubMed Central Google Scholar
• Menendez JA, Vellon L, Lupu R . Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells. Med Hypotheses 2005; 64: 997–1001.
  Article CAS PubMed Google Scholar
• Vazquez-Martin A, Ropero S, Brunet J, Colomer R, Menendez JA . Inhibition of fatty acid synthase (FASN) synergistically enhances the efficacy of 5-fluorouracil in breast carcinoma cells. Oncol Rep 2007; 18: 973–980.
  CAS PubMed Google Scholar
• Knowles LM, Axelrod F, Browne CD, Smith JW . A fatty acid synthase blockade induces tumor cell-cycle arrest by down-regulating Skp2. J Biol Chem 2004; 279: 30540–30545.
  Article CAS PubMed Google Scholar
• Browne CD, Hindmarsh EJ, Smith JW . Inhibition of endothelial cell proliferation and angiogenesis by orlistat, a fatty acid synthase inhibitor. Faseb J 2006; 20: 2027–2035.
  Article CAS PubMed Google Scholar
• Knowles LM, Yang C, Osterman A, Smith JW . Inhibition of fatty-acid synthase induces caspase-8-mediated tumor cell apoptosis by up-regulating DDIT4. J Biol Chem 2008; 283: 31378–31384.
  Article CAS PubMed PubMed Central Google Scholar
• Duran RV, Oppliger W, Robitaille AM, Heiserich L, Skendaj R, Gottlieb E et al. Glutaminolysis activates Rag-mTORC1 signaling. Mol Cell 2012; 47: 349–358.
  Article CAS PubMed Google Scholar
• Deberardinis RJ, Sayed N, Ditsworth D, Thompson CB . Brick by brick: metabolism and tumor cell growth. Curr Opin Genet Dev 2008; 18: 54–61.
  Article CAS PubMed PubMed Central Google Scholar
• DeBerardinis RJ, Mancuso A, Daikhin E, Nissim I, Yudkoff M, Wehrli S et al. Beyond aerobic glycolysis: transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci USA 2007; 104: 19345–19350.
  Article CAS PubMed PubMed Central Google Scholar
• Kamata S, Kishimoto T, Kobayashi S, Miyazaki M, Ishikura H . Possible involvement of persistent activity of the mammalian target of rapamycin pathway in the cisplatin resistance of AFP-producing gastric cancer cells. Cancer Biol Ther 2007; 6: 1036–1043.
  Article CAS PubMed Google Scholar
• Robinson MM, McBryant SJ, Tsukamoto T, Rojas C, Ferraris DV, Hamilton SK et al. Novel mechanism of inhibition of rat kidney-type glutaminase by bis-2-(5-phenylacetamido-1,2,4-thiadiazol-2-yl)ethyl sulfide (BPTES). Biochem J 2007; 406: 407–414.
  Article CAS PubMed PubMed Central Google Scholar
• Seltzer MJ, Bennett BD, Joshi AD, Gao P, Thomas AG, Ferraris DV et al. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1. Cancer Res 2010; 70: 8981–8987.
  Article CAS PubMed PubMed Central Google Scholar
• Chiarini F, Grimaldi C, Ricci F, Tazzari PL, Evangelisti C, Ognibene A et al. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia. Cancer Res 2010; 70: 8097–8107.
  Article CAS PubMed Google Scholar
• Gatenby RA, Gillies RJ . Why do cancers have high aerobic glycolysis? Nat Rev 2004; 4: 891–899.
  Article CAS Google Scholar
• Denko NC . Hypoxia, HIF1 and glucose metabolism in the solid tumour. Nat Rev 2008; 8: 705–713.
  Article CAS Google Scholar
• Zhang H, Bosch-Marce M, Shimoda LA, Tan YS, Baek JH, Wesley JB et al. Mitochondrial autophagy is an HIF-1-dependent adaptive metabolic response to hypoxia. J Biol Chem 2008; 283: 10892–10903.
  Article CAS PubMed PubMed Central Google Scholar
• Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, Kleinman ME et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. Nat Med 2004; 10: 858–864.
  Article CAS PubMed Google Scholar
• Greijer AE, de Jong MC, Scheffer GL, Shvarts A, van Diest PJ, van der Wall E . Hypoxia-induced acidification causes mitoxantrone resistance not mediated by drug transporters in human breast cancer cells. Cell Oncol 2005; 27: 43–49.
  CAS PubMed PubMed Central Google Scholar
• Wykoff CC, Beasley NJ, Watson PH, Turner KJ, Pastorek J, Sibtain A et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res 2000; 60: 7075–7083.
  CAS PubMed Google Scholar
• Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC, Colgan SP . Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 2002; 62: 3387–3394.
  CAS PubMed Google Scholar
• Krishnamurthy P, Ross DD, Nakanishi T, Bailey-Dell K, Zhou S, Mercer KE et al. The stem cell marker Bcrp/ABCG2 enhances hypoxic cell survival through interactions with heme. J Biol Chem 2004; 279: 24218–24225.
  Article CAS PubMed Google Scholar
• Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316: 1039–1043.
  Article CAS PubMed Google Scholar
• Pennacchietti S, Michieli P, Galluzzo M, Mazzone M, Giordano S, Comoglio PM . Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003; 3: 347–361.
  Article PubMed Google Scholar
• Raspaglio G, Filippetti F, Prislei S, Penci R, De Maria I, Cicchillitti L et al. Hypoxia induces class III beta-tubulin gene expression by HIF-1alpha binding to its 3' flanking region. Gene 2008; 409: 100–108.
  Article CAS PubMed Google Scholar
• Zeng L, Kizaka-Kondoh S, Itasaka S, Xie X, Inoue M, Tanimoto K et al. Hypoxia inducible factor-1 influences sensitivity to paclitaxel of human lung cancer cell lines under normoxic conditions. Cancer Sci 2007; 98: 1394–1401.
  Article CAS PubMed Google Scholar
• Kronblad A, Hedenfalk I, Nilsson E, Pahlman S, Landberg G . ERK1/2 inhibition increases antiestrogen treatment efficacy by interfering with hypoxia-induced downregulation of ERalpha: a combination therapy potentially targeting hypoxic and dormant tumor cells. Oncogene 2005; 24: 6835–6841.
  Article CAS PubMed Google Scholar
• Sullivan R, Graham CH . Hypoxia prevents etoposide-induced DNA damage in cancer cells through a mechanism involving hypoxia-inducible factor 1. Mol Cancer Therapeutics 2009; 8: 1702–1713.
  Article CAS Google Scholar
• Wen W, Ding J, Sun W, Wu K, Ning B, Gong W et al. Suppression of cyclin D1 by hypoxia-inducible factor-1 via direct mechanism inhibits the proliferation and 5-fluorouracil-induced apoptosis of A549 cells. Cancer Res 2010; 70: 2010–2019.
  Article CAS PubMed Google Scholar
• Altieri DC . Survivin, cancer networks and pathway-directed drug discovery. Nat Rev 2008; 8: 61–70.
  Article CAS Google Scholar
• Chen N, Chen X, Huang R, Zeng H, Gong J, Meng W et al. BCL-xL is a target gene regulated by hypoxia-inducible factor-1{alpha}. J Biol Chem 2009; 284: 10004–10012.
  Article CAS PubMed PubMed Central Google Scholar
• Erler JT, Cawthorne CJ, Williams KJ, Koritzinsky M, Wouters BG, Wilson C et al. Hypoxia-mediated down-regulation of Bid and Bax in tumors occurs via hypoxia-inducible factor 1-dependent and -independent mechanisms and contributes to drug resistance. Mol Cell Biol 2004; 24: 2875–2889.
  Article CAS PubMed PubMed Central Google Scholar
• Flamant L, Notte A, Ninane N, Raes M, Michiels C . Anti-apoptotic role of HIF-1 and AP-1 in paclitaxel exposed breast cancer cells under hypoxia. Mol Cancer 2010; 9: 191.
  Article PubMed PubMed Central CAS Google Scholar
• Piret JP, Minet E, Cosse JP, Ninane N, Debacq C, Raes M et al. Hypoxia-inducible factor-1-dependent overexpression of myeloid cell factor-1 protects hypoxic cells against tert-butyl hydroperoxide-induced apoptosis. J Biol Chem 2005; 280: 9336–9344.
  Article CAS PubMed Google Scholar
• Mayes PA, Campbell L, Ricci MS, Plastaras JP, Dicker DT, El-Deiry WS . Modulation of TRAIL-induced tumor cell apoptosis in a hypoxic environment. Cancer Biol Ther 2005; 4: 1068–1074.
  Article CAS PubMed Google Scholar
• Pei GT, Wu CW, Lin WW . Hypoxia-induced decoy receptor 2 gene expression is regulated via a hypoxia-inducible factor 1alpha-mediated mechanism. Biochem Biophys Res Commun 2010; 391: 1274–1279.
  Article CAS PubMed Google Scholar